Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solriamfetol for ADHD in Adults
NCT04839562Phase 3Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2021
- Primary completion
- Jan 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing Solriamfetol Arm with Placebo Arm (2 arms). Primary endpoints: Adult ADHD Investigator Symptom Rating Scale Total Score at 6 weeks and A Priori Definition of Clinical Improvement at 6 weeks. Started Aug 2021; status: completed.
02
Drugs
solriamfetol
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT04839562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04839562.